Omeros Corp. (OMER) announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 or MASP-2 program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology, clinical signs and clinical chemistries. Omeros expects to submit a European Clinical Trial Application or CTA in the second quarter of this year to begin trials assessing OMS721.
Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system - an important component of the immune system.
The company has conducted a series of in vivo studies that suggest that MASP-2 inhibition may have a preventive or therapeutic effect in the treatment of atypical hemolytic uremic syndrome (aHUS), HUS, wet age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria, transplant-related complications, ischemia-reperfusion injury, and other immune-related disorders.
The trials reported today in both primates and rodents provide the primary safety data expected to support the initiation of OMS721 studies in mid-year 2013.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.